Corrigendum to "Long-term follow-up of renal function in patients treated with migalastat for Fabry disease" [Bichet et al., MGM Reports; 28 (2021) 100786]

Affiliations

¹ Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montreal, Quebec, Canada.
² Inherited Renal Disorders, Nephrology Department, Fundació Puigvert, REDINREN, IIB Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Department of Medicine, University of Alabama, Birmingham, AL, USA.
⁴ Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK.
⁵ Medical Genetics Service, Department of Genetics, Institute of Biosciences, Institute of Basic Health Sciences, Faculty of Medicine, Faculty of Pharmacy (UFRGS) and National Institute of Population Medical Genetics (INAGEMP), Porto Alegre, Brazil.
⁶ Amicus Therapeutics, Inc., Cranbury, NJ, USA.
⁷ Department of Medical Endocrinology and Metabolism, Rigshospitalet, National University Hospital, Copenhagen University, Copenhagen, Denmark.
⁸ Institute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX, USA.
⁹ Department of Nephrology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.

Published Erratum

Daniel G Bichet et al. Mol Genet Metab Rep. 2021.

. 2021 Oct 2:29:100807.

doi: 10.1016/j.ymgmr.2021.100807. eCollection 2021 Dec.

¹ Department of Medicine, Hôpital du Sacré-Coeur, University of Montréal, Montreal, Quebec, Canada.
² Inherited Renal Disorders, Nephrology Department, Fundació Puigvert, REDINREN, IIB Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
³ Department of Medicine, University of Alabama, Birmingham, AL, USA.
⁴ Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London, UK.
⁵ Medical Genetics Service, Department of Genetics, Institute of Biosciences, Institute of Basic Health Sciences, Faculty of Medicine, Faculty of Pharmacy (UFRGS) and National Institute of Population Medical Genetics (INAGEMP), Porto Alegre, Brazil.
⁶ Amicus Therapeutics, Inc., Cranbury, NJ, USA.
⁷ Department of Medical Endocrinology and Metabolism, Rigshospitalet, National University Hospital, Copenhagen University, Copenhagen, Denmark.
⁸ Institute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, TX, USA.
⁹ Department of Nephrology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.

Abstract

[This corrects the article DOI: 10.1016/j.ymgmr.2021.100786.].

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease.
Bichet DG, Torra R, Wallace E, Hughes D, Giugliani R, Skuban N, Krusinska E, Feldt-Rasmussen U, Schiffmann R, Nicholls K. Bichet DG, et al. Mol Genet Metab Rep. 2021 Aug 4;28:100786. doi: 10.1016/j.ymgmr.2021.100786. eCollection 2021 Sep. Mol Genet Metab Rep. 2021. PMID: 34401344 Free PMC article.